anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Leptospirosis is a global zoonotic disease affecting humans, domestic, and wild animals. Leptospira are typically shed in the urine of reservoir hosts which persist in suitable environments where incidental host transmission occurs after direct contact with infected urine or contaminated environments. Interestingly, serologically identical L. borgpetersenii serovar Hardjo strains JB197 and HB203 show divergent disease severity in the hamster model; JB197 causes severe acute infection while HB203 causes persistent chronic infection. Historically, serovar Hardjo was limited to culture at 29 °C, but utilization of HAN media allows propagation from host tissues at 37 °C. Here, the proteome of strains JB197 and HB203 were characterized after culture from experimentally challenged hamsters at 29 °C and 37 °C. Comparative analyses of JB197 and HB203 samples cultured at 29 °C yielded 425 significantly differentially expressed (DE) proteins, while strains at 37 °C yielded 613 DE proteins including prominent outer membrane proteins and known virulence factors. In agreement, membrane protein GO terms were identified by STRING network analyses along with numerous metabolic KEGG pathways consistent with condition differences. Within strain, JB197 cultured at 29 °C vs 37 °C identified 529 DE proteins, while HB203 identified 524 DE proteins. Investigating differential protein profiles provide insights into strain specific behaviors with implications for better understanding host-pathogen interactions, disease transmission, and response to environmental conditions which can contribute to vaccine development, diagnostic improvement, and ultimately leptospirosis control. SIGNIFICANCE: Leptospirosis is a devastating zoonotic disease affecting humans, wild and domestic animals around the globe. Different species and serovars of Leptospira can affect various animal host species differently; for instance, a serovar that is asymptomatic in the rat may cause severe disease in a dog or human. These differences in host response are not only found at the species and serovar level for Leptospira, but also at the strain level. A prime example comes from strains JB197 and HB203, both species L. borgpetersenii, both serovar Hardjo. Interestingly, JB197 causes a severe acute infection in the hamster while HB203 causes an asymptomatic chronic infection. Understanding these unique relationships between pathogen and host species is important, especially in the context of prevention technologies such as vaccine design, where the strain of Leptospira used as a bacterin might have different efficiencies in different hosts. In this study, proteomic profiles of strains JB197 and HB203 were analyzed, and results revealed diverse protein expression profiles of outer membrane proteins, as well as proteins functioning in motility and growth.
The invention discloses a Chinese herbal extract with anti-dropping and oil-controlling effects. Active components of the Chinese herbal extract are prepared from the following raw materials of: by weight, 10-20 parts of red sage root, 5-10 parts of Chinese angelica, 10-15 parts of sophora flavescens, 5-8 parts of Ligusticum wallichii, 5-8 parts of matrimony vine, 5-10 parts of pericarpium zanthoxyli, 4-8 parts of ligustrum lucidum, 10-15 parts of radix scrophulariae, 5-8 parts of bitter orange and 6-10 parts of root of kudzu vine. The Chinese herbal extract provided by the invention has good anti-dropping and oil-controlling effects. Its preparation method is simple. The product obtained is green and safe, has substantial efficacy, and is in favor of stimulating hair follicle, activating scalp cells and enhance blood circulation. The Chinese herbal extract itself has effects of invigorate blood circulation, promoting qi, preventing hair dropping and controlling oil, and especially has a better curative effect in allusion to seborrheic alopecia.
Every year approximately 12,000 men are diagnosed with prostate cancer in the Netherlands and approximately 2,400 die of this disease. When prostate cancer is limited to the prostate, patients can be operated or radiated with a curative intention, however, metastasized disease is incurable. Initially, prostate cancer responds to testosterone at castration level and treatment with androgen receptor signaling inhibitors. However, after an average of 24 months, prostate cancer will reach a castration resistant stage (mCRPC), which is associated with high morbidity and mortality. Since the introduction of Docetaxel in 2004, multiple treatments for mCRPC have become available. All these treatments have a proven beneficial effect on quality of life and all expand life expectancy. An important clinical problem is that approximately 50% of older patients are not able or not willing to receive docetaxel treatment. These patients are also not eligible for treatments of docetaxel refractory disease. Therefore, there is a need for effective treatments with little site effects.

In the phase 3, ALSYMPCA study 921 patients were randomized between Rad-223 (Xofigo®) and placebo in a 2:1 distribution1. Patients with symptomatic bone metastases, limited lymph node involvement, adequate bone marrow, kidney and liver functions were included in this trial. Patients were previously treated with docetaxel or could not receive docetaxel, declined docetaxel or docetaxel was not available. At a planned interim analysis after 538 deaths, the primary end point overall survival (OS) was 14.9 months in the Radium-223 treated arm and 11.3 months in the placebo arm (HR 0.70; 95% CI 0.58-0.83). All secondary end points were at the favor of Radium-223 treated patients, including time to first skeletal related event, quality of life and various biochemical end points. However, patient reported pain scores were not collected in the trial. Radium-223 treatment was well tolerated, with the most prominent side effects (all grades) thrombocytopenia 12 and 6%, neutropenia 5 and 1% and diarrhea 25 and 15% in the Radium-223 and placebo arm, respectively.

A post-hoc analysis showed an equal efficacy of Radium-223 treatment in docetaxel pre-treated patients as in docetaxel naïve patients.

In this registry the investigators aim to evaluate the efficacy of Radium-223 treatment and first subsequent therapy in a non-study population. Various parameters will be collected, including changes in patient reported pain score. Moreover, changes in serum and blood levels of biomarkers of bone metabolism and levels of blood osteoclast precursors in Radium-223 treated patients will be evaluated for their potential to predict treatment outcome.
The invention discloses a traditional Chinese medicine composition for treating a cardio-cerebrovascular disease. The traditional Chinese medicine composition is prepared from the following medicinal raw materials in parts by weight: 6 parts of astragalus root, 6 parts of salvia, 2 parts of panax notoginseng, 2 parts of ligusticum chuanxiong Hort. and 2 parts of prepared arisacma consanguineum. The traditional Chinese medicine dropping pill for treating the cardio-cerebrovascular disease is prepared from an effective part and a matrix, wherein the effective part is the traditional Chinese medicine composition for treating the cardio-cerebrovascular disease, is prepared from the steps of extracting-alcohol precipitating and macroporous resin adsorption and mainly contains four extractives of the astragalus root and panax notoginseng total saponins, the astragalus root and panax notoginseng total polysaccharides, ligusticum chuanxiong Hort. total volatile oil as well as the salvia and the prepared arisacma consanguineum total phenolic acid. A preparation method of the traditional Chinese medicine dropping pill comprises following the steps: adding the effective part in the melted matrix, uniformly mixing, dripping the mixture in a coolant, and then taking out the pill after condensation. Verified by pharmacological experiments, the product has good therapeutic effects in a coronary heart disease and cerebral apoplexy.
The GOIZ ZAINDU pilot trial is a one-year controlled, randomized, multidomain intervention trial, for prevention of cognitive decline, carried out in the municipality of Beasain in the Basque Country (Spain). Participants were recruited in collaboration with the primary care center health providers from Beasain Municipality after an informative prevention campaign on lifestyle and dementia.

After the baseline evaluation, all participants received in person verbal information on the potential benefits of caring for vascular risk factors, adhering to Mediterranean diet, and having good cognitive and physical activity routines. Participants were later randomly assigned to a standard health advice control group (RHA, control) or the multidomain intervention group (MD-Int). Random assignment followed a proportion of 1:1 and was stratified by age (\<75 years vs.≥75 years), sex, and cognitive status (normal cognition vs. MCI).

1. Regular health advice control (RHA) group. Participants randomized to the control group followed preventive programs already ongoing at their Primary Care Unit regarding physical activity, socialization, and smoking and alcohol usage. Visits to the GP and nurse depended on personal demands and necessities; nevertheless, annual consultation was recommended for all patients over 60 years old.
2. Multidomain intervention (MD-Int) group. The MD-Int program was designed to provide tools and routines that participants could incorporate into daily living activities and reinforce the social environment. Although the program included standardized guidelines and exercises, each participant was considered individually, adapting nutritional requirements and physical and cognitive activity according to individual needs and abilities. This methodology is based on the FINGER trial design\[23\] but has been adapted to local resources and the healthcare system. GPs and nurses were involved in the follow-up visits. Most intervention activities were carried out at the local Primary Care Centre. Local town hall resources such as group activities for older adults at the municipality sports centre and current outdoor sports activities were incorporated in the study. The MD-Int program included: 1) individual follow-up visits every three months for cardiovascular risk factor monitoring and nutritional counselling with primary health care providers; 2) two nutritional workshops led by a nutritionist; 3) 20 hours of cognitive stimulation delivered through group sessions and 4) 40 hours of individual cognitive training exercises. Participants in the MD-Int group received recommendations to practice 2 to 6 hours of physical exercise per week and get involved in sports activities. Social stimulation was promoted through group activities.
The study involves parents/caregivers of infants, ≥ 5 months but \< 11 months of age. Parents who enrolled their infants complete a 1-month blinded placebo run-in period, followed by randomization to placebo or the food supplement.

During the intervention period, infants randomized to the food supplement are fed a once daily, individual packet of the food supplement mixed into liquid (e.g., breast milk, infant formula) or solid (e.g., applesauce, pureed carrots) foods being fed to the infant. The food supplement is a blend of 16 common allergenic proteins (\[oat, milk, egg, sesame, wheat\] \[almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut\] \[cod, shrimp, salmon\]) combined with 400 IU of Vitamin D3. Parents complete a daily diary about any reactions or symptoms within 2 hours of ingesting the food supplement. Infants randomized to the placebo are also fed a once daily individual packet of the placebo mixed into liquid or solid foods being fed to the infant. Parents also complete a daily diary about any reactions or symptoms within 2 hours of ingesting the placebo.
Pregabalin capsules treatment was associated with creatine kinase elevations. Mean changes in creatine kinase from baseline to the maximum value were 60 U/L for pregabalin capsules-treated patients and 28 U/L for the placebo patients. In all controlled trials in adult patients across multiple patient populations, 1.5% of patients on pregabalin capsules and 0.7% of placebo patients had a value of creatine kinase at least three times the upper limit of normal. Three pregabalin capsule-treated subjects had events reported as rhabdomyolysis in premarketing clinical trials. The relationship between these myopathy events and pregabalin capsules are not completely understood because the cases had documented factors that may have caused or contributed to these events. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if these muscle symptoms are accompanied by malaise or fever. Discontinue treatment with pregabalin capsules if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.
A stackable routing clip for installation on machinery using a weld tool. The stackable routing clip has a body and at least one wing section. A weld projection extends from a lower face of the body. Each wing section may extend from the body and include a routing port that receives the insertion of a cable tie used to secure cables to the stackable routing clip. The stackable routing clip is configured so that a plurality of the stackable routing clips may be grouped together to form a stack. The clips may be stacked together in a dispenser that is used to dispense of individual clips when a clip is to be welded by the weld tool to the machinery. The weld tool may melt the weld projection and plunge the clip into the resultant molten metal for a quick and strong weld.
A method, computer program product, and computer system for encoding, by a computing device, a transcript and text macros into vector representations. A word by word report may be predicted based upon, at least in part, the encoding. An attention mechanism may be queried based upon, at least in part, a decoder state. An attention distribution may be produced over an encoder output. An interpolation of the encoder output may be produced based upon, at least in part, the attention distribution. The interpolation of the encoder output may be input into a decoder for report modeling that includes text macro location and content.
PURPOSE:To obtain a foamy acid hair dye excellent in hair dyeing ability and foam stability, containing a benzyl alcohol or pyrrolidone compound, sulfo group-contg. anionic surfactant, acid dye, acid and propellant gas agent at specified proportions. CONSTITUTION:This hair dye contains 0.5-20wt.% of at least one kind of compound of formula I (R1 is H, CH3 or CH3O; R2 is CH2OH, CH2CH2OH, C(CH3)2 OH, etc.) or formula II (R3 is a 1-18C alkyl), 0.01-3wt.% of at least one kind of sulfo group-contg. anionic surfactant, 0.005-2wt.% of an acid dye, an acid (e.g. citric acid) and l-20wt.% of a propellant gas agent. The amount of the acid to be used is set at such a level that the stock solution containing the above ingredients stand at pH2.0-4.5. This hair dye may contain high-molecular compound(s) such as xanthan gum or hydroxyethyl cellulose; presence of such high-molecular compound(s) stabilizes the stock solution for a long period, facilitating its handling during use and also improving foam stability.
This is an open-label, randomized, comparative, multinational study. The study will be looking at the kidney function of kidney transplant recipients, while also comparing the safety and the effects (good and bad) of three different combinations of immunosuppression drugs in combination with prednisone, following treatment with Daclizumab (Zenapax). The three combinations are; (1) sirolimus and tacrolimus followed by the withdrawal of tacrolimus after three months; (2) sirolimus and mycophenolate mofetil (MMF); and (3) tacrolimus and MMF. The participants will be required to return to throughout the next 24 months following their transplant for physical exams, chest x-ray, blood, and urine tests. Participants will be put into one of three groups, and receive the study drugs starting on the day of transplant. Due to some drugs affecting the drug levels of sirolimus, participants need to agree not to take any new drugs during the study unless approved by the study doctor.
Patients receive PLX038 IV over 1 hour on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, biopsy, as well as blood and stool sample collection during screening and on the trial.
The present application discloses compositions and methods of synthesis and use of 18F or 19F labeled molecules of use in PET or MRI imaging. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a metal complex and binding of the 18F- or 19F-metal complex to a chelating moiety. Alternatively, the metal may first be conjugated to the chelating group and subsequently the 18F or 19F bound to the metal. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The 18F or 19F labeled targetable construct peptides are stable in serum at 37°C for a sufficient time to perform PET or MRI imaging.
The invention relates to a drug for treating hemorrhoids. The drug for treating the hemorrhoids comprises internal drug and drug for external use. The internal drug is prepared from 20-35 g of fig fruit, 25-30 g of preserved meat, 3-5 g of obscured homalomenarhizome, 6-9 g of fructus choerospondiatis, 2-4 g of plantain, 1-2 g of cocklebur fruits, 5-8 g of Chinese wolfberries, 6-8 g of radix glycyrrhizae preparata and 4-7 g of bunge cherry seeds. The drug for external use is prepared from 7-9 g of climbing groundsel herbs, 4-7 g of fimbriae orostachys, 3-5 g of herba aristolochiae, 5-9 g of garden burnet, 3-5 g of plantain, 2-5 g of radix curcumae, 6-9 g of pagoda tree fruits, 7-9 g of magnets, 12-15 g of charcoal and 30-40 g of pine seed oil. The drug is prepared from traditional Chinese medicine and safe in use. An oral administration and external use combined treatment mode is adopted, the cure rate is high, the drug can take effect fast, the side effects are eliminated in the using process due to compatibility, by being prepared through a special method, the medicine can be matched more reasonably and promote one another, and the curative effect is improved.
A composition for preventing and treating diseases caused by vascular damage is provided to inhibit damage of vascular endothelial cell and destruction of blood-retinal barrier. The composition for preventing and treating diseases caused by vascular damage comprises the processed extract of Panax sp. plants having a ratio of ginsenosides (Rg3+Rg5+Rk1)/(Rb1+Rb2+Rc+Rd) of 1.0 or more, wherein the processed extract of Panax sp. plants having 1.0 or more of a ratio of ginsenosides (Rg3+Rg5+Rk1)/(Rb1+Rb2+Rc+Rd) is prepared by heating the extract of Panax sp. Plants at 70-150 deg.C for 2-6 hours; the Panax sp. is Panax ginseng, Panax quinquefolia, Panax notoginseng, Panax japonica, Panax trifolia, Panax pseudoginseng, Panax vietnamensis, Panax elegatior, Panax wangianus or Panax bipinratifidus; and the disease caused by vascular damage is ischemic disease or diabetic complication.
Acute pancreatitis (AP) is a multifaceted inflammatory disorder stemming from the aberrant activation of trypsin within the pancreas. Despite the contribution of various factors to the pathogenesis of AP, such as trypsin activation, dysregulated increases in cytosolic Ca2+ levels, inflammatory cascade activation, and mitochondrial dysfunction, the precise molecular mechanisms underlying the disease are still not fully understood. Mitophagy, a cellular process that preserves mitochondrial homeostasis under stress, has emerged as a pivotal player in the context of AP. Research suggests that augmenting mitophagy can mitigate pancreatic injury by clearing away malfunctioning mitochondria. Elucidating the role of mitophagy in AP may pave the way for novel therapeutic strategies. This review article aims to synthesize the current research findings on mitophagy in AP and underscore its significance in the clinical management of the disorder.
Chronic low back pain (cLBP) is the second most frequent chronic pain condition in the United States and results in billions of dollars each year in health care expenses, disability and lost productivity. A major factor that contributes to the refractory nature of cLBP is enhanced pain sensitivity, which is an altered state of pain processing that amplifies pain sensation and impairs descending pain inhibition. Enhanced pain sensitivity in patients who develop cLBP is associated with altered expression of pro-nociceptive and inflammatory genes. On the other hand, regular physical activity of at least moderate intensity for 150 or more minutes per week is recommended to reduce pain severity and improve function in individuals with cLBP. Therefore, a deeper mechanistic understanding of the effect of physical activity on the neurophysiologic and gene transcription alterations that characterize cLBP may inform more specific treatment options to optimize pain reduction and reduce the risk of pain chronicity.

The purpose of this longitudinal cohort pilot study is to examine the feasibility, acceptability, and preliminary efficacy of the Problem-solving Pain to Enhance Living Well (PROPEL) self-management (SM) intervention on cLBP. This pre-post intervention study will recruit 40 community dwelling adults (age 18 - 60 years old) with cLBP. They will receive electronic video modules focused on cLBP SM knowledge and weekly phone consultations to facilitate monitoring and problem-solving. All participants will be assessed for primary outcomes including cLBP SM behaviors, physical activity, pain severity and interferance, and pain sensitivity at baseline and every 2 weeks for 12 weeks. The study will examine differential neurophysiologic and gene expression profiles between participants with cLBP at 12-weeks post-intervention and correlate these outcome measures to total duration of physical activity.
Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.